Stay up-to-date with the latest research and clinical updates on renal cell carcinoma from the 2024 ASCO GU Symposium.
Dr. Barragán-Carrillo explains the potential benefits of camu camu in reducing tumor size.
Dr. Brian Rini discusses KEYNOTE-564 long-term survival data and LITESPARK-005 PROs.
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
While IV nivolumab has improved patient outcomes, there is a need for different administration options to improve efficiency.
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
The study's second phase analyzed data from patients with RCC scheduled to undergo radical or partial nephrectomy.
While belzutifan offers beneficial PFS and ORR rates, it also offers longer TTD and better PRO results versus everolimus.
New research presented at ASCO GU 2024 by Mehul Gupta, MD, described TFS rates after multiple first-line therapies.
Dr. Grünwald details the CLEAR study and a subgroup analysis on the efficacy of lenvatinib/pembrolizumab for aRCC.
Drs. Barata and Wallis highlight the efficacy of pem/len and how this IO/TKI approach compares to other strategies for aRCC.
A retrospective study of patients with accRCC offers understandings of the role of tivozanib in the current RCC landscape.
The combination previously demonstrated improved progression-free survival, overall survival, and objective response rate.
Researchers investigated the potential long-term benefits of nivolumab plus ipilimumab.
Advertisement
Advertisement
